Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

May 08, 2018; 90 (19) ArticleOpen Access

Prevalence of preclinical Alzheimer disease

Comparison of current classification systems

Silke Kern, Henrik Zetterberg, Jürgen Kern, Anna Zettergren, Margda Waern, Kina Höglund, Ulf Andreasson, Hanna Wetterberg, Anne Börjesson-Hanson, Kaj Blennow, Ingmar Skoog
First published April 13, 2018, DOI: https://doi.org/10.1212/WNL.0000000000005476
Silke Kern
From the Department of Neuropsychiatric Epidemiology Unit (S.K., J.K., A.Z., M.W., H.W., A.B.-H., I.S.) and Clinical Neurochemistry Laboratory (S.K., H.Z., K.H., U.A., K.B.,), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henrik Zetterberg
From the Department of Neuropsychiatric Epidemiology Unit (S.K., J.K., A.Z., M.W., H.W., A.B.-H., I.S.) and Clinical Neurochemistry Laboratory (S.K., H.Z., K.H., U.A., K.B.,), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jürgen Kern
From the Department of Neuropsychiatric Epidemiology Unit (S.K., J.K., A.Z., M.W., H.W., A.B.-H., I.S.) and Clinical Neurochemistry Laboratory (S.K., H.Z., K.H., U.A., K.B.,), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Zettergren
From the Department of Neuropsychiatric Epidemiology Unit (S.K., J.K., A.Z., M.W., H.W., A.B.-H., I.S.) and Clinical Neurochemistry Laboratory (S.K., H.Z., K.H., U.A., K.B.,), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margda Waern
From the Department of Neuropsychiatric Epidemiology Unit (S.K., J.K., A.Z., M.W., H.W., A.B.-H., I.S.) and Clinical Neurochemistry Laboratory (S.K., H.Z., K.H., U.A., K.B.,), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kina Höglund
From the Department of Neuropsychiatric Epidemiology Unit (S.K., J.K., A.Z., M.W., H.W., A.B.-H., I.S.) and Clinical Neurochemistry Laboratory (S.K., H.Z., K.H., U.A., K.B.,), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulf Andreasson
From the Department of Neuropsychiatric Epidemiology Unit (S.K., J.K., A.Z., M.W., H.W., A.B.-H., I.S.) and Clinical Neurochemistry Laboratory (S.K., H.Z., K.H., U.A., K.B.,), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanna Wetterberg
From the Department of Neuropsychiatric Epidemiology Unit (S.K., J.K., A.Z., M.W., H.W., A.B.-H., I.S.) and Clinical Neurochemistry Laboratory (S.K., H.Z., K.H., U.A., K.B.,), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Börjesson-Hanson
From the Department of Neuropsychiatric Epidemiology Unit (S.K., J.K., A.Z., M.W., H.W., A.B.-H., I.S.) and Clinical Neurochemistry Laboratory (S.K., H.Z., K.H., U.A., K.B.,), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaj Blennow
From the Department of Neuropsychiatric Epidemiology Unit (S.K., J.K., A.Z., M.W., H.W., A.B.-H., I.S.) and Clinical Neurochemistry Laboratory (S.K., H.Z., K.H., U.A., K.B.,), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingmar Skoog
From the Department of Neuropsychiatric Epidemiology Unit (S.K., J.K., A.Z., M.W., H.W., A.B.-H., I.S.) and Clinical Neurochemistry Laboratory (S.K., H.Z., K.H., U.A., K.B.,), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Prevalence of preclinical Alzheimer disease
Comparison of current classification systems
Silke Kern, Henrik Zetterberg, Jürgen Kern, Anna Zettergren, Margda Waern, Kina Höglund, Ulf Andreasson, Hanna Wetterberg, Anne Börjesson-Hanson, Kaj Blennow, Ingmar Skoog
Neurology May 2018, 90 (19) e1682-e1691; DOI: 10.1212/WNL.0000000000005476

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
2194

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective To determine the prevalence of preclinical Alzheimer disease (AD) according to current classification systems by examining CSF from a representative general population sample of 70-year-olds from Gothenburg, Sweden.

Method The sample was derived from the population-based H70 Gothenburg Birth Cohort Studies in Gothenburg, Sweden. The participants (n = 322, age 70 years) underwent comprehensive neuropsychiatric, cognitive, and somatic examinations. CSF levels of β-amyloid (Aβ)42, Aβ40, total tau, and phosphorylated tau were measured. Preclinical AD was classified according to criteria of the A/T/N system, Dubois 2016, National Institute on Aging–Alzheimer's Association (NIA-AA) criteria, and International Working Group-2 (IWG-2) criteria. Individuals with Clinical Dementia Rating score >0 were excluded, leaving 259 cognitively unimpaired individuals.

Results The prevalence of amyloid pathology was 22.8%, of total tau pathology was 33.2%, and of phosphorylated tau pathology was 6.9%. With the A/T/N system, the prevalence of A+/T−/N− was 13.1%, A+/T−/N+ was 7.3%, A+/T+/N+ was 2.3%, A−/T−/N+ was 18.9%, and A−/T+/N+ was 4.6%. When the Dubois criteria were applied, the prevalence of asymptomatic at risk for AD was 36.7% and of preclinical AD was 9.7%. With the NIA-AA criteria, the prevalence of stage 1 was 13.1% and stage 2 was 9.7%. With the IWG-2 criteria, the prevalence of asymptomatic at risk for AD was 9.7%. The APOE ε4 allele was associated with several of the categories. Men more often had total tau pathology, A+/T−/N+, preclinical AD according to Dubois 2016, asymptomatic at risk for AD according to the IWG-2 criteria, and NIA-AA stage 2.

Conclusion The prevalence of pathologic AD markers was very common (46%) in a representative population sample of 70-year-olds. The clinical implications of these findings need to be scrutinized further in longitudinal studies.

Glossary

Aβ=
β-amyloid;
AD=
Alzheimer disease;
AR-AD=
at risk for Alzheimer disease;
CDR=
Clinical Dementia Rating;
CFAS=
Cognitive Function and Ageing;
DSM-III-R=
Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised;
DSM-V=
Diagnostic and Statistical Manual of Mental Disorders, 5th edition;
IWG-2=
International Working Group-2;
LP=
lumbar puncture;
MCI=
mild cognitive impairment;
MMSE=
Mini-Mental State Examination;
NIA-AA=
National Institute on Aging–Alzheimer’s Association;
p-tau=
phosphorylated tau;
SNAP=
non–Alzheimer disease pathophysiology;
SNP=
single nucleotide polymorphism;
t-tau=
total tau

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • The Article Processing Charge was funded by Swedish Research Council.

  • Received September 28, 2017.
  • Accepted in final form February 20, 2018.
  • Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

View Full Text

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Author contributions
    • Study funding
    • Disclosure
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • Alzheimer's disease
  • Cohort studies
  • Prevalence studies

Alert Me

  • Alert me when eletters are published
Neurology: 100 (6)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise